Acyclovir Sodium Injection, Solution
NDC Package 84549-155-20
Package Information
Acyclovir Sodium injection is a medication used in certain people to treat outbreaks of herpes simplex infection of the skin (such as on the genitals), mucous membrane areas (such as the mouth, nose), or brain. This formulation utilizes a injection, solution delivery system. Marketed by Propharma Distribution, this product is identified by NDC 84549-155 and is authorized under FDA application ANDA203701.
Identification & Billing
- RxCUI: 1734934 - acyclovir sodium 1000 MG in 20 ML Injection
- RxCUI: 1734934 - 20 ML acyclovir 50 MG/ML Injection
- RxCUI: 1734934 - 20 ML acycycloguanosine 50 MG/ML Injection
- RxCUI: 1734934 - acyclovir 1000 MG per 20 ML Injection
- RxCUI: 1734934 - acyclovir 50 MG/ML (equivalent to acyclovir sodium 54.9 MG/ML) per 20 ML Injection
Clinical Specifications
- DNA Polymerase Inhibitors - [MoA] (Mechanism of Action)
- Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor - [EPC] (Established Pharmacologic Class)
- Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor - [EPC] (Established Pharmacologic Class)
- Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor - [EPC] (Established Pharmacologic Class)
- Nucleoside Analog - [EXT]
Regulatory & Marketing
Hierarchy Structure
- 84549 - Propharma Distribution
- 84549-155 - Acyclovir Sodium
- 84549-155-20 - 20 mL in 1 VIAL, SINGLE-DOSE
- 84549-155 - Acyclovir Sodium
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 84549-155-20 identifies a specific commercial package of 20 ml in 1 vial, single-dose of Acyclovir Sodium, a human prescription drug labeled by Propharma Distribution. This injection, solution is formulated for intravenous use and contains acyclovir sodium as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Propharma Distribution on October 11, 2013. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used in certain people to treat outbreaks of herpes simplex infection of the skin (such as on the genitals), mucous membrane areas (such as the mouth, nose), or brain. It is also used in certain people to treat shingles infection. The viruses that cause these infections live in the body quietly until an outbreak occurs. Acyclovir does not cure these infections, but can speed healing of the sores, decrease pain/itching/formation of new sores, and lower the risk of other problems from the virus (e.g., infection spreading to other parts of the body/organs, persistent pain after sores heal).
How is this Propharma Distribution product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 84549015520. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.